Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mainz Biomed NV MYNZ

Healthcare Biotechnology
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of... see more

Recent & Breaking News (NDAQ:MYNZ)

Mainz Biomed to Ring Nasdaq Stock Market Closing Bell

GlobeNewswire March 21, 2022

Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study

GlobeNewswire March 17, 2022

Mainz Biomed Announces Year End 2021 Results

GlobeNewswire March 9, 2022

Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month

GlobeNewswire March 2, 2022

Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert

GlobeNewswire February 23, 2022

Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach

GlobeNewswire February 14, 2022

Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board

GlobeNewswire February 9, 2022

Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert

GlobeNewswire February 4, 2022

Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire January 28, 2022

Mainz Biomed Appoints Steve Quinn as VP Business Development

GlobeNewswire January 27, 2022

Mainz Biomed Announces Pricing of Follow-on Offering

GlobeNewswire January 25, 2022

Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert

GlobeNewswire January 19, 2022

Mainz Biomed Appoints Michele Pedrocchi, Former Head of Roche Diagnostics Business Development, to Strategic Advisory Board

GlobeNewswire January 12, 2022

Mainz Biomed to Present at the H.C. Wainwright Bioconnect Virtual Conference

GlobeNewswire January 11, 2022

Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers

GlobeNewswire January 5, 2022

Mainz BioMed Appoints Karen Richards as Vice President, Regulatory Affairs to Lead US FDA Approval Process

GlobeNewswire December 21, 2021

Mainz Biomed Expands ColoAlert Commercialization with GANZIMMUN Diagnostics in Europe

GlobeNewswire December 14, 2021

Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during Covid-19 Pandemic

GlobeNewswire December 7, 2021

Mainz Biomed Establishes Partnership with Precision for Medicine to Support ColoAlert's U.S. Regulatory and Commercial Strategy

GlobeNewswire November 30, 2021

Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board

GlobeNewswire November 18, 2021